[The use of anagrelide to treat thrombocytosis in connection with the chronic myeloproliferative disease].
Jantunen
Esa
E
KYS:n sisätautien klinikka, Kuopio. esa.jantunen@kuh.fi
Penttilä
Karri
K
Kuittinen
Taru
T
Nousiainen
Tapio
T
D000284:Administration, Oral; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005387:Finland; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009196:Myeloproliferative Disorders / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D011446:Prospective Studies; D011799:Quinazolines / Q000627:therapeutic use*; D018570:Risk Assessment; D013922:Thrombocytosis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
D011799:Quinazolines; C021139:anagrelide